Institut Necker-Enfants Malades (INEM), INSERM U1151, CNRS UMR 8253, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants Malades, Paris, France; Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Leibniz Institute, Berlin, Germany.
Clin Immunol. 2018 Jan;186:26-31. doi: 10.1016/j.clim.2017.07.020. Epub 2017 Jul 21.
B cells are the only cell type that can give rise to antibody-producing cells, and the only cell type whose selective depletion can, today, lead to an improvement of a wide range of immune-mediated inflammatory diseases, including disorders not primarily driven by autoantibodies. Here, I discuss this paradoxical observation, and propose that the capacity of B cells to act as cytokine-producing cells explains how they can control monocyte activity and subsequently disease pathogenesis. Together with current data on the effect of anti-CD20 B cell-depleting reagents in the clinic, this novel knowledge on B cell heterogeneity opens the way for novel safer and more efficient strategies to target B cells. The forthcoming identification of disease-relevant B cell subsets is awaited to permit their monitoring and specific targeting in a personalized medicine approach.
B 细胞是唯一能够产生抗体产生细胞的细胞类型，也是唯一能够选择性耗尽的细胞类型，这种选择性耗尽可以改善广泛的免疫介导的炎症性疾病，包括不是主要由自身抗体驱动的疾病。在这里，我讨论了这一矛盾的观察结果，并提出 B 细胞能够作为细胞因子产生细胞的能力解释了它们如何控制单核细胞的活性，进而影响疾病的发病机制。结合目前在临床上使用抗 CD20 B 细胞耗竭试剂的效果数据，关于 B 细胞异质性的这一新知识为靶向 B 细胞的新型、更安全、更有效的策略开辟了道路。即将确定与疾病相关的 B 细胞亚群，以便在个性化医疗方法中对其进行监测和特异性靶向。
